- ISIN
- US88025U1097
- CUSIP
- 88025U109
- Sector
- Healthcare
- Industry
- Health Information Services
- IPO Date
- Sep 12, 2019
Highlights
- Market Cap
- $6.00B
- Enterprise Value
- $5.60B
- EPS (TTM)
- -$0.18
- Total Revenue (TTM)
- $638.78M
- Gross Profit (TTM)
- $444.61M
- EBITDA (TTM)
- -$5.89M
- Year Range
- $11.16 - $50.34
- Target Price
- $22.14
- ROA (TTM)
- -2.23%
- ROE (TTM)
- -2.78%
- Avg. Volume (1M)
- 3M
- Avg. Volume Value (1M)
- $127.35M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TXG Performance Chart
10x Genomics, Inc. (TXG) is up 189.8% since the beginning of the year. At $47 per share, TXG is trading 6.1% below its 52-week high of $50. Investors who bought $1,000 worth of TXG shares 5 years ago would now be looking at an investment worth $258.
Loading charts...
Compare this symbol against anything
Returns By Period
10x Genomics, Inc. (TXG) has returned 189.82% so far this year and 261.39% over the past 12 months.
10x Genomics, Inc.
- 1D
- -4.37%
- 1M
- 21.17%
- 6M
- 134.01%
- YTD
- 189.82%
- 1Y
- 261.39%
- 3Y*
- -8.77%
- 5Y*
- -23.74%
- 10Y*
- —
- ALL TIME*
- -1.92%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
TXG Monthly Returns History
Based on dividend-adjusted daily data since Sep 12, 2019, TXG's average daily return is +0.08%, while the average monthly return is +1.37%. At this rate, an investment would double in approximately 4.2 years.
Historically, 52% of months were positive and 48% were negative. The best month was Nov 2022 with a return of +42.2%, while the worst month was Apr 2022 at -37.2%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.
On a daily basis, TXG closed higher 49% of trading days. The best single day was Nov 10, 2022 with a return of +24.4%, while the worst single day was Oct 10, 2024 at -24.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 23.85% | 14.11% | -7.90% | 3.86% | 28.37% | 35.45% | 23.29% | 189.82% | |||||
| 2025 | 4.46% | -28.73% | -18.33% | -5.27% | 15.24% | 21.51% | 16.15% | 4.16% | -16.56% | 16.68% | 37.90% | -13.29% | 13.58% |
| 2024 | -25.54% | 11.93% | -19.53% | -21.98% | -23.43% | -13.25% | 6.27% | 12.97% | -3.30% | -29.01% | -0.81% | -9.69% | -74.34% |
| 2023 | 28.51% | 1.47% | 17.40% | -6.02% | 0.06% | 6.44% | 12.79% | -17.67% | -20.44% | -14.47% | 23.36% | 28.58% | 53.57% |
| 2022 | -35.37% | -15.37% | -6.63% | -37.22% | 7.18% | -11.60% | -11.27% | -17.83% | -13.67% | -4.56% | 42.24% | -5.74% | -75.54% |
| 2021 | 20.87% | 4.00% | 1.69% | 9.28% | -9.00% | 8.79% | -6.43% | -3.99% | -17.25% | 10.78% | -5.25% | -2.52% | 5.20% |
Benchmark Metrics
10x Genomics, Inc. has an annualized alpha of -1.41%, beta of 1.43, and R2 of 0.18 versus S&P 500 Index. Calculated based on daily prices since September 12, 2019.
- This stock participated in 192.34% of S&P 500 Index downside but only 163.28% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.18 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -1.41%
- Beta
- 1.43
- R²
- 0.18
- Upside Capture
- 163.28%
- Downside Capture
- 192.34%
Return for Risk
Risk / Return Rank
TXG ranks 97 for risk / return — above 97% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TXG | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.20 | ||
| Sortino ratioReturn per unit of downside risk | +1.87 | ||
| Omega ratioGain probability vs. loss probability | 1.43 | 1.25 | +0.18 |
| Calmar ratioReturn relative to maximum drawdown | 9.03 | 2.00 | +7.03 |
| Martin ratioReturn relative to average drawdown | 21.75 | 8.49 | +13.26 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the 10x Genomics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the 10x Genomics, Inc. was 96.47%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current 10x Genomics, Inc. drawdown is 76.64%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-96.47%Apr 2025 | 3y 11mo | — | 5y 3moApr 2021 - now | 2025 selloff2025 |
-51.63%Mar 2020 | 1mo 24d | 4mo 29d | 6mo 23dJan 2020 - Aug 2020 | COVID crash2020 |
-28.33%Mar 2021 | 20d | 29d | 1mo 19dFeb 2021 - Apr 2021 | — |
-25.69%Oct 2019 | 13d | 1mo 13d | 1mo 26dSep 2019 - Nov 2019 | — |
-21.20%Nov 2020 | 22d | 2mo 2d | 2mo 24dOct 2020 - Jan 2021 | — |
Drawdown Indicators
| TXG | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.47% | -56.78% | -39.69% |
Max Drawdown (1Y)Largest decline over 1 year | -28.03% | -9.10% | -18.93% |
Max Drawdown (3Y)Largest decline over 3 years | -87.79% | -18.90% | -68.89% |
Max Drawdown (5Y)Largest decline over 5 years | -96.26% | -25.43% | -70.83% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -76.64% | -1.58% | -75.06% |
Average DrawdownAverage peak-to-trough decline | -60.10% | -10.70% | -49.40% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.62% | 2.14% | +9.48% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of 10x Genomics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how 10x Genomics, Inc. is priced in the market compared to other companies in the Health Information Services industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TXG relative to other companies in the Health Information Services industry. Currently, TXG has a P/S ratio of 9.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TXG in comparison with other companies in the Health Information Services industry. Currently, TXG has a P/B value of 7.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TXG
Add 10x Genomics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TXG